Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

14.50
+1.6212.58%
Post-market: 14.870.3700+2.55%19:59 EDT
Volume:12.43M
Turnover:174.90M
Market Cap:1.43B
PE:-2.49
High:14.58
Open:13.22
Low:13.20
Close:12.88
52wk High:39.89
52wk Low:12.73
Shares:98.32M
Float Shares:80.72M
Volume Ratio:2.64
T/O Rate:15.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-4.90
PE(LYR):-2.49

Loading ...

Ultragenyx Pharma Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
May 21

Ultragenyx price target raised to $96 from $84 at Cantor Fitzgerald

TIPRANKS
·
May 21

Ultragenyx director Shehnaaz Suliman disposes 5,740 common shares for $144,228.8

Reuters
·
May 19

Ultragenyx shareholders approve amended 2023 incentive plan at annual meeting

Reuters
·
May 19

Ultragenyx price target lowered to $33 from $34 at Evercore ISI

TIPRANKS
·
May 12

Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD), IN8bio (INAB) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
May 11

Ultragenyx Pharmaceutical (RARE) Valuation Check After Recent Share Price Momentum And Long Term Pressure

Simply Wall St.
·
May 11

Ultragenyx Pharma Is Maintained at Buy by Guggenheim

Dow Jones
·
May 08

Ultragenyx price target lowered to $43 from $52 at Guggenheim

TIPRANKS
·
May 08

Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference

GlobeNewswire
·
May 07

Stock Track | Ultragenyx Pharmaceutical Soars 5.32% Intraday on Positive Analyst Ratings

Stock Track
·
May 06

Ultragenyx Pharma Is Maintained at Neutral by Wedbush

Dow Jones
·
May 06

Wedbush Trims Price Target on Ultragenyx Pharmaceutical to $26 From $27, Maintains Neutral Rating

MT Newswires Live
·
May 06

Ultragenyx Pharmaceutical (RARE) Receives a Buy from Wells Fargo

TIPRANKS
·
May 06

Barclays Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
May 06

Ultragenyx Pharmaceutical Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 06

REFILE-Ultragenyx Q1 revenue drop steeper than estimated; backs FY view

Reuters
·
May 06

Ultragenyx Pharmaceutical Q1 EPS $(1.84) Misses $(1.51) Estimate, Sales $136.000M Miss $158.777M Estimate

Benzinga Earnings
·
May 06

BRIEF-Ultragenyx Q1 EPS USD -1.84

Reuters
·
May 06

Ultragenyx Q1 net loss widens to $185 million; revenue slips to $136 million

Reuters
·
May 06